CM Life Sciences II Inc. (CMIIU) Income Statement Analysis – Financial Results

See more : Parkway Acquisition Corp. (PKKW) Income Statement Analysis – Financial Results

Complete financial analysis of CM Life Sciences II Inc. (CMIIU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CM Life Sciences II Inc., a leading company in the Shell Companies industry within the Financial Services sector.

SomaLogic and Twist Bioscience Corporation announce partnership to discover novel therapeutic targets and antibodies

August 18, 2021globenewswire.com

BOULDER, Colo. & SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences II (Nasdaq: CMIIU) and SomaLogic, Inc., a leader in AI-data driven proteomics technology, and Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to...

ARK Investment Leans Into Biotech and Telecom Holdings

July 12, 2021gurufocus.com

Catherine Wood (Trades, Portfolio)'s ARK Investment has revealed additions to three biotechnology and telecommunications holdings according to GuruFocus' Real-Time Picks, a Premium feature.

SomaLogic Customizable Protein Panels With Industry-Leading 7,000-Plex Assay Now Available

July 6, 2021businesswire.com

NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)--CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, Inc., a global leader in proteomics technology, announced today that their new customizable protein panel products are now available to pharma, biotechnology and academic research customers seeking...

SomaLogic Latest to Take SPAC Route to Public Markets

April 2, 2021gurufocus.com

SomaLogic is joining the growing number of companies going public via special purpose acquisition companies. The Boulder, Colorado-based health care company plans to merge with CM Life Sciences II Inc. (NASDAQ:CMIIU), whose lead entity is Casdin Capital LLC, a life-sciences...

CM Life Sciences II Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $240 Million Initial Public Offering

February 22, 2021businesswire.com

NEW YORK--(BUSINESS WIRE)--CM Life Sciences II Inc. (the “Company”) announced today that it priced its initial public offering of 24,000,000 units at $10.00 per unit. The units will be listed on The Nasdaq Capital Market (“Nasdaq”) and trade under the...

Source: https://incomestatements.info
Category: Stock Reports